Findings

What do systematic reviews say?

9 questions · 9 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 33.3%Moderate 5 · 55.6%High 1 · 11.1%

Oral 5‐ASA vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA showed no clear difference in adverse events compared with comparator 5‐ASA (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.01 [0.92, 1.12]
9 studies · 1576 participants
Moderate

Oral 5‐ASA vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Serious adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA showed no clear difference in serious adverse events compared with comparator 5‐ASA (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.59 [0.22, 1.56]
4 studies · 677 participants
Low

Oral 5‐ASA vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA showed no clear difference in withdrawal due to adverse events compared with comparator 5‐ASA (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.94 [0.57, 1.54]
9 studies · 1489 participants
Moderate

Oral 5‐ASA vs SASP

Adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA probably leads to lower adverse events compared with SASP (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.48 [0.36, 0.63]
12 studies · 909 participants
Moderate

Oral 5‐ASA vs placebo

Adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA showed no clear difference in adverse events compared with placebo (high certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.95 [0.85, 1.07]
8 studies · 1218 participants
High

Oral 5‐ASA vs SASP

Serious adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA showed no clear difference in serious adverse events compared with SASP (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.36 [0.28, 6.52]
2 studies · 107 participants
Low

Oral 5‐ASA vs placebo

Serious adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.53 [0.18, 1.56]
4 studies · 746 participants
Low

Oral 5‐ASA vs SASP

Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA probably leads to lower withdrawal due to adverse events compared with SASP (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.4 [0.24, 0.68]
10 studies · 640 participants
Moderate

Oral 5‐ASA vs placebo

Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA probably leads to lower withdrawal due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.72 [0.54, 0.97]
13 studies · 2372 participants
Moderate